Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that HDAC inhibitors, such as Vorinostat and Entinostat, could be effective in promoting hair regrowth in a mouse model of alopecia areata.

This study found that inhibiting class I histone deacetylases in postnatal mouse dermal cells preserved their ability to induce hair follicles during culture by increasing specific gene expressions and activating the Wnt signaling pathway.

This study found that securinine and ajmaline significantly inhibited hepatocellular carcinoma cell viability and induced apoptosis, with securinine showing lower toxicity to normal liver cells.

This study reviewed competing endogenous RNA networks related to skin aging and wound healing, finding mechanisms like UVB-induced senescence and photoaging, as well as potential therapeutic targets for improving skin health and recovery.

This study identified key genes linked to immune cells and potential therapeutic compounds for alopecia areata by evaluating upregulated genes from patient datasets, highlighting T and NK cell involvement in hair follicle attack and suggesting drug candidates through molecular docking and dynamics simulations.

This review summarizes recent findings on the role of lactylation, a novel post-translational modification, in skin diseases, suggesting its potential as a therapeutic target by linking metabolism, epigenetic regulation, and inflammatory processes.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

This review discusses epigenetic mechanisms in tissue repair across species and summarizes recent CRISPR-based technologies as promising tools for studying and enhancing tissue regeneration, but reports no new experimental results.

In a pilot study with 21 patients, the niostem device increased hair counts and density and enhanced testers’ self-perception of hair growth at 6 months without reported adverse effects, suggesting potential benefits for androgenetic alopecia.

The researchers reported that using Natesto® testosterone gel improved erectile function and mood in hypogonadal men over a 90-day period.

In this pilot study, the niostem device, a wearable device delivering low-level electrical stimulation, significantly increased hair density by 19.3% and thickness by 8.8% in male androgenetic alopecia patients over six months without reported adverse events.

This review discusses the development and potential therapeutic applications of steroid sulfatase inhibitors for hormone-dependent disorders and cognitive dysfunction, reporting no new clinical results.

In this study, lysocellin induced G1 phase arrest in human osteosarcoma cells, but diminished the cytotoxic efficacy of etoposide, while its derivative alopestatin may reduce etoposide-induced alopecia in a rat model.

This review examines patents and publications on steroid sulfatase inhibitors since 1999 and reports no new clinical results, highlighting their potential for treating estrogen- and androgen-driven conditions.

This pilot study suggests that lovastatin may counteract stress-induced MICA expression in hair follicles and enhance MICA shedding, potentially offering a complementary approach for alopecia areata treatment.

This study found that stilbamidine and hydroxystilbamidine can inhibit the release of specific enzymes from lysosomes and mitochondria in rabbit liver at certain concentrations, with effects similar to cortisol and chloroquine.

This study found that inhibiting JAK signaling can unexpectedly trigger hair growth in resting-phase mouse skin, implicating JAK-STAT pathways and oncostatin M in maintaining hair follicle stem cell quiescence.

This study found that cilostazol promoted hair growth in human dermal papilla cells and mouse models, suggesting its potential as a therapeutic target for alopecia treatment.

In this study, the novel isoprenylcysteine analog SIG-1451 was shown to inhibit pro-inflammatory cytokine release in various cell-based assays relevant to allergic dermatitis, acting on targets such as IL-4 and IL-6 with potential anti-inflammatory benefits.

This review discusses the medicinal chemistry of steroid sulfatase inhibitors for estrogen- and androgen-dependent disorders but reports no new clinical results.

In this study, viprostol was not effective in promoting hair growth for men with androgenetic alopecia over a 24-week period.

This study found that topical Vorinostat induced significant hair regrowth in mice with alopecia areata, suggesting it as a potential repurposable treatment for the condition.

This study evaluated the effect of statins on alopecia areata improvement in a large retrospective cohort and found that statins do not independently predict improvement in this hair disorder. Age and intralesional triamcinolone acetonide injections were identified as better predictors.

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.

This study found that trilostane was effective in resolving symptoms such as polyuria and polydipsia in many dogs with pituitary-dependent hyperadrenocorticism, with significant hormone level reductions observed.

This study evaluated a new anti-baldness product, IPSTiC patch hair, designed to treat androgenetic alopecia, and reported that it effectively inhibits NO radical and 5α-reductase activity while maintaining safety and stability, suggesting its potential for topical use.

This study developed cilostazol-loaded formulations for nose-to-brain delivery, finding that these formulations improved cilostazol's bioavailability by enhancing solubility, absorption, and permeability, achieving nearly 100% drug release in vitro within 2 hours.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

This study concluded that statins do not independently improve alopecia areata, as age confounds their perceived efficacy.